Labcorp Holdings (LH) announced the commercial release of its H5 bird flu molecular test to support the diagnosis of human H5 bird flu infections.
The test, developed with the support of the Centers for Disease Control and Prevention, is available in the US for physicians to order for suspected H5N1 infections in people, the company said Tuesday in a statement.
Health-care providers can order the test for suspected cases using nasopharyngeal swab specimens to analyze polymerase chain reactions, the company said.
The US faces a multistate poultry and dairy cow outbreak of H5 bird flu with recent cases found in industry workers.
Labcorp shares rose 1% in recent Tuesday trading.
Price: 231.81, Change: +2.19, Percent Change: +0.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.